Versartis Inc (NASDAQ:VSAR)

Data as of Jan 30
 -0.79 / -4.27%
Today’s Change
Today|||52-Week Range
Health Technology

Company Description

Versartis, Inc. is an endocrine-focused biopharmaceutical company. It develops long-acting therapeutic proteins for the treatment of endocrine disorders. The company develops new therapeutic proteins utilizing the novel half-life extension technology XTEN. Versartis was founded by Jeffrey L. Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman on December 10, 2008 and is headquartered in Redwood City, CA.

Contact Information

Versartis, Inc.
275 Shoreline Drive
Redwood City California 94065
P:(650) 963-8580
Investor Relations:
(212) 213-0006



Individual stakeholders47.05%
Mutual fund holders23.31%
Other institutional22.21%

Top Executives

Jeffrey L. ClelandPresident, Chief Executive Officer & Director
Joshua T. BrummChief Financial Officer
Eric HumphrissVice President-Clinical Operations
Paul B. WestbergSenior Vice President-Business Development
Patrick M. MurphyVice President-Manufacturing

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2015 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2015. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2015 and/or its affiliates.